A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors
A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors
Recruiting · NCT06827613 · Registry updated 2025-09-24Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors | HR+, HER2-, Advanced Breast Cancer; Triple Negative Locally Advanced Non-resectable Breast Cancer | Recruiting | Phase 1 / Phase 2 | 2025-09-24 | NCT06827613 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Marengo Therapeutics, Inc. | 2 |
8 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| BC Cancer | Vancouver | Canada | 1 |
| Massachusetts General Hospital Cancer Center | Boston | United States | 178 |
| Ohio State University Comprehensive Cancer Center | Columbus | United States | 1 |
| Princess Margaret Cancer Centre | Toronto | Canada | 9 |
| Sarah Cannon Research Institute | Nashville | United States | 119 |
| UCLA Health | Los Angeles | United States | 13 |
| Usc Norris Comprehensive Cancer Center | Los Angeles | United States | 67 |
| UT Health San Antonio MD Anderson Cancer Center | San Antonio | United States | 3 |